Objective: Care of critically ill children includes sedation but current therapies are suboptimal. To describe dexmedetomidine use in children supported on mechanical ventilation for acute respiratory failure. Design: Secondary analysis of data from the Randomized Evaluation of Sedation Titration for Respiratory Failure clinical trial. Setting: Thirty-one PICUs. Patients: Data from 2,449 children; 2 weeks to 17 years old. Interventions: Sedation practices were unrestrained in the usual care arm. Patients were categorized as receiving dexmedetomidine as a primary sedative, secondary sedative, periextubation agent, or never prescribed. Dexmedetomidine exposure and sedation and clinical profiles are described. Measurements and Main Results: Of 1,224 usual care patients, 596 (49%) received dexmedetomidine. Dexmedetomidine as a primary sedative patients (n = 138; 11%) were less critically ill (Pediatric Risk of Mortality III-12 score median, 6 [interquartile range, [3] [4] [5] [6] [7] [8] [9] [10] [11] ) and when compared with all other cohorts, experienced more episodic agitation. In the intervention group, time in sedation target improved from 28% to 50% within 1 day of initiating dexmedetomidine as a primary sedative. Dexmedetomidine as a secondary sedative usual care patients (n = 280; 23%) included more children with severe pediatric acute respiratory distress syndrome or organ failure. Dexmedetomidine as a secondary sedative patients experienced more inadequate pain (22% vs 11%) and sedation (31% vs 16%) events. Dexmedetomidine S edation management is fundamental to the care of critically ill children supported on mechanical ventilation. Although practice variation exists, the most common sedation strategy in pediatric critical care includes the concomitant administration of an opioid and benzodiazepine (1) (2) (3) (4) . The use of these agents is associated with adverse effects contributing to intensive care morbidity, such as decreased spontaneous ventilation and prolonged mechanical ventilation. Further, γ-aminobutyric acid agonists, such as benzodiazepines (3), demonstrate neurotoxic apoptotic effects, and when used to provide anesthesia at a young age, may impact neurocognitive development (5, 6) .
Dexmedetomidine is an α2-adrenoceptor agonist principally acting centrally in the locus ceruleus to produce sedation, as well as in the spinal cord resulting in analgesia. Unlike most sedatives used in intensive care, dexmedetomidine preserves respiratory drive, allowing for sedation with maintenance of spontaneous breathing. In critically ill adults, sedation with dexmedetomidine has been shown to provide adequate levels of sedation while reducing the duration of delirium and/or coma and shortening the duration of mechanical ventilation (7) (8) (9) . Of particular interest to the pediatric population, animal models demonstrate a neuroprotective effect (10-13) that requires further clinical investigation.
Although not approved for use in children by the Food and Drug Administration, dexmedetomidine has gained popularity in pediatric critical care. To date, data describing dexmedetomidine use are derived from single-center retrospective cohort studies or case reports (4, (14) (15) (16) (17) (18) . Most often, dexmedetomidine has been used for short durations (< 24 hr) and as an adjunct to other sedative agents. Here we describe dexmedetomidine use in PICUs over a 4-year period using data prospectively collected in a large multicenter study of sedation practices. In addition to describing the change in dexmedetomidine use over time, we describe the sedation and clinical courses of patients receiving dexmedetomidine as a primary agent (DEXp), dexmedetomidine as a secondary agent (DEXs), or to facilitate endotracheal extubation in a cohort of children supported on mechanical ventilation for acute respiratory failure.
METHODS
We performed a secondary analysis of the Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE) study dataset. RESTORE was a cluster randomized trial that compared usual care to a nurse-implemented goal-directed sedation algorithm in children with acute respiratory failure (19) . Thirty-one PICUs participated and were randomized to continued usual care (14 sites, 1,224 patients) or to the intervention (17 sites, 1,225 patients). Prior to randomization, all PICUs implemented the same pain (Face, Legs, Activity, Cry, Consolability pain scale [20] , Wong-Baker FACES pain rating scale [21] , Individualized Numeric Rating Scale [22] (27) severity, daily clinical and organ function data, daily comfort assessments, and sedative dosing data from endotracheal intubation to 72 hours after the last opioid dose.
Most analyses focus on the usual care patients where dexmedetomidine use was unrestrained. In the intervention group, dexmedetomidine use per protocol was limited to the periextubation period in children assessed to be intolerant of an awake state. To facilitate data interpretation, patients were categorized into one of four dexmedetomidine usage groups: 1) dexmedetomidine used as a periextubation agent (DEXe), defined as dexmedetomidine initiated on the day of, or day before, the first planned extubation; 2) DEXp, defined as dexmedetomidine initiated within the first 2 days of intubation and administered for greater than or equal to 50% of intubated days and not used as a periextubation agent; 3) DEXs, defined as dexmedetomidine used but not as a periextubation or primary agent; and 4) dexmedetomidine never prescribed.
Sedation profiles include opioid and benzodiazepine exposure, number of different sedative classes, measures of wakefulness, episodic pain and agitation, and sedation-related adverse events including inadequate pain management (2+ consecutive hours of pain scores, ≥ 4), inadequate sedation management (2+ consecutive hours of SBS, +1/+2), and clinically significant iatrogenic withdrawal (treatment of increased WAT-1 scores) (28) . For patients in the intervention group, we report the percentage of time spent within the prescribed SBS target range.
For the usual care arm, we describe the frequency of dexmedetomidine usage groups by year. Site variability in dexmedetomidine use was evaluated by calculating the percentage of patients managed with dexmedetomidine by site and the intraclass correlation coefficient (ICC). The ICCs were derived from analysis of variance adjusting for age group, PRISM III-12 score, and baseline POPC greater than 1 as performed in the primary trial publication (19) , as well as study year to control for potential time trends in dexmedetomidine use. CIs for the ICCs were constructed using Searle method to adjust for unequal sample sizes across sites (29, 30) . All usual care patients were used in calculating the DEXp ICC, all patients excluding DEXp patients were used in calculating the DEXs ICC, and DEXe and dexmedetomidine never prescribed patients were used in calculating the DEXe ICC.
Baseline patient characteristics were compared across the four dexmedetomidine usage groups using linear, logistic, multinomial logistic, and cumulative logit regression for continuous, binary, nominal, and ordinal variables, respectively. Analyses of sedation and clinical profile data used these methods as well as proportional hazards and Poisson regression for time-to-event and rate variables, respectively. Continuous variables except percentage of study days variables were log-transformed. For duration of mechanical ventilation, we adjusted for age group, PRISM III-12 score, and baseline POPC greater than 1 as performed in the primary trial publication (19) , as well as worst PARDS on days 0 to 1 to control for severity of lung injury. All regression analyses except for primary diagnosis accounted for PICU as a cluster variable using generalized estimating equations. To reflect how decisions are made in clinical practice, sedation and clinical profiles were also compared between 1) DEXp versus all other patients, 2) DEXs versus all other patients excluding DEXp patients, and 3) DEXe versus dexmedetomidine never prescribed, when the overall p value comparing across the four dexmedetomidine groups was less than 0.05. Due to multiple comparisons, p values less than 0.01 were considered to indicate statistically significant differences for the additional comparisons. All data analyses were performed using SAS (version 9.4; SAS Institute, Cary, NC).
RESULTS
In total, 596 of 1,224 (49%) usual care patients ever received dexmedetomidine. DEXp and DEXs use increased each year; specifically, from 6% to 17% for DEXp and 17% to 32% for DEXs. DEXe use remained consistent throughout the 4-year enrollment period ranging from 13% to 17%. The percentage of patients managed with dexmedetomidine varied by site: DEXp 8% (median; range, 0-37%), DEXs 23% (9-32%), and DEXe 12% (4-20%). The ICC indicated moderate variability by site: DEXp 0.081 (95% CI, 0.043-0.173), DEXs 0.050 (0.024-0.117), and DEXe 0.035 (0.012-0.092).
DEXp
Baseline characteristics of usual care patients by dexmedetomidine usage group are presented in Table 1 . The DEXp cohort (n = 138; 11%) included children with lower median PRISM III-12 scores and more children with asthma or reactive airway disease. When used as DEXp, the mean daily dexmedetomidine dose was 0.6 μg/kg/hr (median; interquartile range [IQR], 0.4-0.8), the peak daily dexmedetomidine dose was 0.9 μg/kg/ hr (0.6-1.3), and the cumulative dexmedetomidine dose was 77.0 μg/kg (37.6-167.0). The median duration of DEXp exposure was 6 days (IQR, 4-10) with 28% (n = 39) receiving dexmedetomidine postextubation for a median of 2 days (IQR, 1-3). Table 2 illustrates DEXp sedation profiles on the day dexmedetomidine was initiated followed by two subsequent days. Most DEXp patients were awake and calm with modal SBS scores −1/0. Table 3 compares the sedation profiles by dexmedetomidine usage group. Compared to all other patients, children receiving DEXp were exposed to significantly less opioids (median cumulative dose, 12.4 vs 18.5 mg/kg) but more sedative classes (median, 4 vs 3), propofol (18% vs 10%), and ketamine (38% vs 29%). Children receiving DEXp experienced significantly more study days with any episode of agitation (median, 50% vs 38%). Table 4 compares the clinical profiles by dexmedetomidine usage group. The duration of mechanical ventilation was significantly shorter in the DEXp group compared to all other patients (median, 5.0 vs 6.8 d).
DEXs
The DEXs cohort (n = 280; 23%) included more children with severe PARDS and children with a greater number of organ dysfunctions on admission. When used as DEXs, the mean daily dexmedetomidine dose was 0.5 μg/kg/hr (median; IQR, 0.3-0.7), the peak daily dexmedetomidine dose was 0.7 μg/kg/ hr (0.5-1.1), and the cumulative dexmedetomidine dose was 49.8 μg/kg (19.8-133.5). DEXs was initiated on day 4 (median; IQR, 2-8) postintubation. The median duration of DEXs exposure was 4 days (IQR, 3-9) with 27% (n = 75) receiving dexmedetomidine postextubation for a median of 2 days (IQR, 1-3). Table 5 illustrates DEXs sedation profiles on the day dexmedetomidine was initiated and up to 2 days before and after initiation. Most DEXs patients were awake and calm with modal SBS scores −1/0; on the first day of receiving dexmedetomidine, 18% were agitated with modal SBS scores +1/+2. The percentage of patients receiving neuromuscular blockade was higher on the days before dexmedetomidine was initiated. Compared to all other patients excluding DEXp patients, children receiving DEXs were exposed to significantly more opioids (median cumulative dose, 53.2 vs 13.2 mg/kg), benzodiazepines (42.3 vs 9.5 mg/kg), and sedative classes (median, 4 vs 3). DEXs patients experienced significantly more study days with any episode of pain (median, 30% vs 20%) and agitation (52% vs 33%) compared to all other patients excluding DEXp patients. The DEXs group also experienced significantly more sedation-related adverse events, specifically, inadequate pain management (22% vs 11%), inadequate sedation management (31% vs 16%), and clinically significant iatrogenic withdrawal (15% vs 7%). The duration of mechanical ventilation was significantly longer in the DEXs group compared to all other patients excluding DEXp patients (9.9 vs 5.6 d). The DEXs group also experienced a significantly longer recovery from acute respiratory failure (median, 4.7 vs 2. Acute respiratory failure related to sepsis 13 (9) 40 (14) 18 (10) 141 (22) Asthma or reactive airway disease 26 (19) 29 (10) 28 (16) 37 (6) Aspiration pneumonia 9 (7) 19 (7) 14 (8) 37 (6) Other c 18 (13) 39 (14) 26 (15) 69 (11) Pediatric acute respiratory distress syndrome based on worst OI or OSI on days 0-1, n (%) No. of organ dysfunctions on days 0-1,
IQR = interquartile range, OI = oxygenation index, OSI = oxygen saturation index, PRISM III-12 = Pediatric Risk of Mortality score from first 12 hr in the PICU. a p values for the comparison between groups were calculated using linear, logistic, multinomial logistic, and cumulative logit regression for log-transformed continuous, binary, nominal, and ordinal variables, respectively. All regression analyses except for primary diagnosis accounted for PICU as a cluster variable using generalized estimating equations.
b Pediatric Cerebral Performance Category and Pediatric Overall Performance Category scores range from 1 to 6, with higher categories indicating greater impairment. c Other primary diagnoses include pulmonary edema, thoracic trauma, pulmonary hemorrhage, laryngotracheobronchitis, acute respiratory failure after bone marrow transplantation, acute chest syndrome/sickle cell disease, pertussis, pneumothorax (nontrauma), acute exacerbation lung disease (cystic fibrosis or bronchopulmonary dysplasia), acute respiratory failure related to multiple blood transfusions, pulmonary hypertension (not primary), and other. Renal dysfunction based on age-specific creatinine thresholds. Hepatic dysfunction based on age-and gender-specific ALT thresholds or total bilirubin thresholds. asthma or reactive airways disease, patients known to not tolerate an awake, intubated state. When used as DEXe, the mean daily dexmedetomidine dose was 0.3 μg/kg/hr (median; IQR, 0.1-0.4), the peak daily dexmedetomidine dose was 0.3 μg/kg/ hr (0.2-0.5), and the cumulative dexmedetomidine dose was 11.2 μg/kg (4.9-19.4). The median duration of DEXe exposure was 2 days (IQR, 1-2) with 22% (n = 40) receiving dexmedetomidine postextubation for a median of 1 day (IQR, 1-2). Children receiving DEXe were exposed to significantly more sedative classes (median, 4 vs 2), ketamine (29% vs 24%), and antidelirium medications (4% vs < 1%) compared to the dexmedetomidine never prescribed group. The DEXe group experienced significantly more days with episodic pain (median, 25% vs 17%) and agitation (median, 50% vs 25%) and more inadequate sedation management events (19% vs 15% of patients). Patients prescribed DEXe experienced significantly shorter weaning from mechanical ventilation (2.1 vs 2.3 d).
Dexmedetomidine Use in the Intervention Group
As expected, dexmedetomidine use was much lower in the intervention group, with 287 of 1,225 (23%) intervention patients ever receiving dexmedetomidine. When DEXp was prescribed as a protocol deviation (n = 80; 7%), time in sedation target improved from 28% to 50% within 1 day of initiating dexmedetomidine. No such improvements were noted when DEXs was prescribed as a protocol deviation (n = 152; 12%). When compared with the dexmedetomidine never prescribed cohort (n = 938, 77%), patients in the intervention 
DISCUSSION
We present the sedation and clinical profiles of mechanically ventilated children receiving dexmedetomidine over a 4-year period within a large multicenter clinical trial. Our data indicate that dexmedetomidine use is increasing as both a primary and secondary agent in pediatric critical care. We report that clinicians are prescribing DEXp more often in children who are less critically ill, and, in the intervention group, DEXp resulted in more time within the prescribed sedation target. Adding DEXs into an existing sedative regime does not appear to add benefit. DEXe is prescribed more often in patients who experienced a difficult sedation course (more episodic pain and agitation and inadequate sedation management) or in those known not to tolerate an awake, intubated state; specifically, patients with reactive airways disease or asthma. When prescribed, DEXe shortened the ventilator weaning process. The ideal sedation agent in pediatric critical care would effectively produce anxiolysis in a wide range of patient age and developmental levels, preserve spontaneous ventilation, and exhibit a short half-life. In addition, the ideal sedation agent would not be associated with physiologic tolerance with continued use or produce adverse effects including the potential for long-term neurocognitive dysfunction. While the pharmacologic and pharmacodynamics properties of dexmedetomidine meet most of these criteria, symptoms characteristic of sympathetic over activity including tachycardia, hypertension, emesis, agitation, and seizures have been reported in children upon dexmedetomidine discontinuation and warrant further study (18, (31) (32) (33) (34) .
Data supporting the use of DEXp in pediatrics are limited (35) . In adult critical care, multiple large randomized controlled clinical trials support DEXp as an effective sedation agent that shortens the duration of mechanical ventilation and length of ICU stay (7, 8) . Here we report a large cohort of critically ill children who were adequately sedated with DEXp for a median of 6 days. In our cohort, children prescribed DEXp were less critically ill with a short anticipated length of mechanical ventilation, such as children with asthma but without multisystem organ failure.
DEXp was opioid sparing but was associated with the use of more sedative classes. With light levels of sedation, it is not surprising that those receiving DEXp experienced more intermittent episodes of agitation. Importantly, despite an increase in episodic agitation, we did not identify an increase in unplanned removal of medical devices. Of note, when prescribed in the intervention group as a protocol deviation,
Sedation-related adverse events
Inadequate pain management, n (%)
22 (16) 61 (22) 27 (15) 64 (10 14 (10) 41 (15) 14 (8) 45 (7) < 0.001 0.64 < 0.001 0.21
Extubation failure (reintubation within 24 hr), n (%)
13 (9) 37 (13) 17 (10) 37 ( DEXp was associated with a rapid achievement of targeted sedation scores.
Even after adjusting for severity of illness, DEXp was associated with a shorter duration of mechanical ventilation, possibly due to the more awake state and use of less opioids known to depress spontaneous respiration. Literature describing the use of dexmedetomidine in children after cardiac surgery also suggests that dexmedetomidine is effective as a primary agent and may facilitate earlier extubation (36, 37) . Pending further investigation, data may support the use of DEXp as a superior sedative agent in pediatric populations where the duration of mechanical ventilation is expected to be short.
As a secondary agent, however, dexmedetomidine did not improve the patient's sedation profile. Adding DEXs into the sedative regime of complex PARDS patients with a median of two or more organ dysfunctions did not result in an appreciable improvement in patient comfort nor did DEXs reduce other sedative dosing. This finding is in contrast to that of Neurologic testing, n (%) 20 (14) 66 (24) 21 (12) 123 (20 DEXe = dexmedetomidine as a periextubation agent, DEXp = dexmedetomidine as a primary agent, DEXs = dexmedetomidine as a secondary agent, IQR = interquartile range. a p values for the comparison between groups were calculated using proportional hazards and logistic regression accounting for PICU as a cluster variable using generalized estimating equations for time-to-event and binary variables, respectively. b Patients were assigned 28 d of mechanical ventilation if they remained intubated or were transferred or died prior to day 28 without remaining extubated for 24 hr, therefore making the outcome equivalent to ventilator-free days. c Time to recovery from acute respiratory failure was defined as the duration from day 0 start (endotracheal intubation, initiation of assisted breathing for chronically trached patients, or PICU admission for patients intubated at an outside hospital) to the time that the patient first met criteria to be tested for extubation readiness (spontaneously breathing and oxygenation index ≤ 6). Excludes nonsurvivors who did not meet criteria prior to death. For survivors who never met criteria, the duration of recovery was set equal to the duration of mechanical ventilation if the patient was successfully extubated or to 28 d if the patient was still intubated on day 28 or transferred to another PICU still intubated. Calculated for 135 dexmedetomidine as a primary agent (DEXp), 267 dexmedetomidine as a secondary agent (DEXs), 177 dexmedetomidine as a periextubation agent (DEXe), and 577 dexmedetomidine never prescribed patients. Duration of weaning from mechanical ventilation was defined as the duration from the time that the patient first met criteria to be tested for extubation readiness to successful endotracheal extubation (remained extubated for > 24 hr) or successful removal of assisted breathing for trached patients. Excludes nonsurvivors who were not extubated for > 24 hr prior to death. Also excludes survivors who never met criteria or were still intubated on day 28. Calculated for 111 DEXp, 212 DEXs, 159 DEXe, and 478 dexmedetomidine never prescribed. e PICU and hospital length of stay exclude all nonsurvivors. Patients still in the PICU or hospital on day 90 were censored at day 90.
others who report a reduction (4) or plateau (18) in opioid and benzodiazepine dosing after starting a dexmedetomidine infusion. The profile and characteristics of the pediatric patient most likely to have either a comfort or reduced sedative burden benefit remain unclear, but this analysis suggests it is not useful as a secondary agent in complex pediatric patients.
The use of DEXe was stable over our 4-year enrollment. We found that patients receiving DEXe were weaned from mechanical ventilation earlier but, again, did not experience less opioid or benzodiazepine exposure as previously reported in pediatric cohort studies (14, (37) (38) (39) (40) and case reports (41) (42) (43) (44) (45) . Similar to difficult-to-extubate adult patients (46) , DEXe improves the rate of successful extubation. Our analyses are vulnerable to design flaws and bias. Unmeasured factors may have impacted a clinician's decision to prescribe dexmedetomidine. Without patient-level randomization, one cannot evaluate the impact of dexmedetomidine on clinical outcomes. In addition, delirium was not systematically assessed in the parent trial, and its presence may have impacted both the dose and number of sedative classes administered. Also, nonpharmacologic interventions which may impact sedation were not captured. Since dexmedetomidine use was not the objective of the parent study, there may have been an underreporting of dexmedetomidine side effects. Evaluation of dexmedetomidine safety, as well as the potential benefit of dexmedetomidine in facilitating restorative sleep, requires prospective study (47) (48) (49) . Finally, we studied pediatric patients with acute respiratory failure. These data may not apply to other critically ill pediatric cohorts.
CONCLUSIONS
Our data support the use of dexmedetomidine as a primary sedative agent in low criticality children because it offers the benefit of rapid achievement of targeted sedation scores and awake patients whose comfort levels can be better assessed and rapidly managed. Prescribing dexmedetomidine as a secondary sedative agent in a cohort of high criticality children did not appear to add clinical benefit. Finally, using dexmedetomidine to facilitate extubation in children who are intolerant of an awake, intubated state may abbreviate ventilator weaning. These data allow us to broaden our armamentarium of pediatric critical care sedation and inform the design of future randomized controlled clinical trials investigating how dexmedetomidine can be best used in pediatric critical care.
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